Abstract
Aims
Evidence showed that SGLT2 inhibitors have greater protective effects against retinal diseases compared to other hypoglycemic agents. Thus, we explore the association between SGLT2 inhibitor usage and macular degeneration (MD) in Taiwanese patients with diabetes.
Methods
The National Health Insurance (NHI) program's claim data are released as the National Health Insurance Research Database (NHIRD). This database covers more than 99% of the residents in Taiwan. We included data on patients who were newly diagnosed with type 2 diabetes mellitus (ICD-9-CM: 250, exclude 250.1x; ICD-10-CM: E11), with an age at diagnosis of over 20 years as our study population. Patients who received (sodium-glucose cotransporter 2 inhibitor) SGLT2i (ATC code: A10BK) over 90 days in 2016–2019 were defined as the SGLT2i cohort. Conversely, patients who did never received SGLT2i were defined as the non-SGLT2i cohort. The exclusion criteria were having MD before the index date, receiving SGLT2i within 1–89 days, and missing data on sex, age, or days of SGLT2i usage. Two cohorts were matched by 1:1 propensity score matching, which was based on age, sex, payroll bracket grade, urbanization, comorbidities, and medications.
Results
Compared to non-SGLT2i cohort, patients who received SGLT2i had a significantly lower risk of MD (adjusted hazard ratio = 0.70, 95%CI = 0.66–0.75).
Conclusions
We found that SGLT2is has a strong protective effect against MD in patients with diabetes. SGLT2is may have benefits beyond glycemic control in patients with DR. However, additional clinical and experimental studies are required.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
A novel type of drug, sodium-glucose cotransporter-2 (SGLT2) inhibitors, has been approved for diabetes treatment by the U.S. Food and Drug Administration (FDA) since 2014 [1]. SGLT2 is primarily expressed in the proximal convoluted tubule and functions as a reabsorption for glucose [2, 3]. SGLT2 inhibitors block the reabsorption of glucose by inhibiting SGLT2, thereby promoting glucose renal excretion; this lowers the elevated glucose levels of patients with diabetes and produces an osmotic diuretic effect [4].
Compared to other antihyperglycemic agents, SGLT2 inhibitors have a lower risk of hypoglycemia because they only affect the reabsorption of glucose that is filtered rather than blood glucose [5,6,7]. Moreover, SGLT2 inhibitors have cardiovascular protective effects and renal benefits [8,9,10,11]. In addition to cardiovascular and kidney problems, however, macular degeneration (MD) is also a complication among patients with diabetes [12,13,14]. A former review showed that the global incidence of MD was 1.59 (95% CrI 1.18–2.11) per 100 person-years [15]. A recent study revealed that from 2005 to 2014 [16], 3.75 to 3.95% of Taiwanese patients with diabetes experienced diabetic eye diseases, and 0.29 to 0.35% encountered poor vision and even blindness. A meta-analysis also showed that SGLT2 inhibitors have greater protective effects against retinal diseases compared to other hypoglycemic agents [17]. However, related evidence about SGLT2 inhibitor usage and MD is limited. Thus, we explore the association between SGLT2 inhibitor usage and MD in Taiwanese patients with diabetes.
Methods
Data source
The National Health Insurance (NHI) program of Taiwan was established in 1995, and this program's claim data are released as the National Health Insurance Research Database (NHIRD). This database covers more than 99% of the residents in Taiwan, and diseases such as type 2 diabetes mellitus or MD can be defined by the International Classification of Diseases, 9th Revision, Clinical Modification, and the International Classification of Diseases, 10th Revision (ICD-9-CM and ICD-10-CM). Additionally, therapeutic uses such as drugs for type 2 diabetes mellitus can be defined by the Anatomical Therapeutic Chemical (ATC) code. All analyses were performed in the Health and Welfare Data Center, and privacy policies were implemented to protect the privacy of beneficiaries. The Institutional Review Board (IRB) of China Medical University (CMUH110-REC3-133) has approved this study.
Study population
We included data on patients who were newly diagnosed with type 2 diabetes mellitus (ICD-9-CM: 250, exclude 250.1x; ICD-10-CM: E11), with an age at diagnosis of over 20 years as our study population. Patients who received (sodium-glucose cotransporter 2 inhibitor) SGLT2i (ATC code: A10BK) over 90 days in 2016–2019 were defined as the SGLT2i cohort. Conversely, patients who did never received SGLT2i were defined as the non-SGLT2i cohort. The index date was defined as the first date of receiving SGLT2i in the SGLT2i cohort and as a random date between 2016 and 2019 in the non-SGLT2i cohort. The exclusion criteria were having MD before the index date, receiving SGLT2i within 1 to 89 days, and missing data on sex, age, or days of SGLT2i usage. Two cohorts were matched by 1:1 propensity score matching, which was based on age, sex, payroll bracket grade, urbanization, comorbidities, and medications.
Main outcome and covariates
All study participants were followed from the index date until the onset of MD (ICD-9-CM: 362.5, ICD-10-CM: H35.3), withdrawal from the NHI program, or the end of 2019. The covariates included sex, age group (20–39, 40–59, 60 + years), payroll bracket grade (low, medium, high), urbanization (high, medium, low), comorbidities, and medications. Payroll bracket grade levels were defined as monthly income < 700 USD, 700–1300 USD, and > 1300 USD, respectively.
Comorbidities diagnosed before the index date, including hypertension (ICD-9-CM: 401–405; ICD-10-CM: I10-I13, I15, and N26.2), dyslipidemia (ICD-9-CM: 272; ICD-10-CM: E71.30, E75.21, E75.22, E75.24, E75.3, E75.5, E75.6, E77, E78.0-E78.6, E78.70, E78.79, E78.8, and E78.9), coronary artery disease (CAD) (ICD-9-CM: 410–414; ICD-10-CM: I20-I25), alcoholism (ICD-9-CM: 291, 303, 305.0, 571.0–571.3, 790.3, V11.3, and V79.1; ICD-10-CM: F10, K70, R78.0, and Z65.8), chronic obstructive pulmonary disease (COPD) (ICD-9-CM: 490–496, and 504–506; ICD-10-CM: J40-J47, and J64-J68), diabetic retinopathy (DR) (ICD-9-CM: 362.0; ICD-10-CM: E11.31-E11.35), and macular edema (ICD-9-CM: 362.83; ICD-10-CM: H35.81), were considered.
Eight common antidiabetic drugs, including metformin, sulphonylurea, meglitinides, a-glucosidase inhibitors (AGI), thiazolidinedione, dipeptidyl peptidase 4 inhibitors (DPP4i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and insulin, were considered.
Statistical method
Mean and standard error (SD) were used to perform characteristics of continuous variables such as age and follow-up time, and percentage was used to perform characteristics of category variables. The difference can be evaluated using the standardized mean difference (SMD). The incidence rate was performed per 1,000 person-years (PY) and was calculated by n/PY*1,000. Univariable and multivariable Cox regression models were used to calculate the hazard ratio and the 95% interval estimation of the hazard ratio. The multivariable Cox regression adjusted age, sex, payroll bracket grade, urbanization, comorbidities, and medications. All analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC, USA), and p values of 0.05 or less were considered statistically significant.
Result
Table 1 presents the demographic characteristics of the two cohorts. There were 147,664 patients matched 1:1 with another 147,664 patients in both cohorts. The SMD shows that age, sex, payroll bracket grade, urbanization, comorbidities, and medications had no significant difference between non-SGLT2i and SGLT2i cohorts. There were approximately 58% male patients among patients with type 2 diabetes mellitus (DM). The major urbanization level was high, with approximately 52%, and the major payroll bracket grade level was medium, with approximately 54%. The top two comorbidities, including hypertension and dyslipidemia, were performed. The proportions of patients receiving medications with and without SGLT2i were as follows: metformin (97.34% versus 97.51%), sulphonylurea (83.63% versus 84.25%), meglitinides (18.06% versus 18.12%), AGI (36.71% versus 35.82%), thiazolidinedione (39.21% versus 37.94%), DPP4i (72.00% versus 71.69%), GLP-1RA (2.02% versus 1.89%), and insulin (40.60% versus 41.55%), respectively. The mean (SD) follow-up times were 2.24 (0.78) years in the study group and 2.21 (0.98) years in the control group.
Table 2 shows the risk of MD according to whether the patients have SGLT2i, comorbidities, or medications. Compared to patients who did not receive SGLT2i, patients who received SGLT2i had a significantly lower risk of MD (adjusted hazard ratio [aHR] = 0.70, 95% CI = 0.66–0.75). For different age groups, we found that patients over 60 had a higher risk of MD compared to those aged 20–39 (aHR = 4.06, 95% CI = 3.17–5.18). There was no significantly different risk of MD between female and male patients. Patients with a payroll bracket grade higher than 700 USD had lower risks of MD than those with a payroll bracket grade lower than 700 USD. Moreover, patients with comorbidities, including CAD (aHR = 1.11, 95% CI = 1.03–1.19), DR (aHR = 2.47, 95% CI = 2.30–2.65), macular edema (aHR = 1.65, 95% CI = 1.32–2.05), as well as those who received medications such as AGI (aHR = 1.16, 95% CI = 1.08–1.24), thiazolidinedione (aHR = 1.09, 95% CI = 1.01–1.16), DPP4i (aHR = 1.12, 95% CI = 1.02–1.22), and insulin (aHR = 1.13, 95% CI = 1.06–1.21) had higher risks of MD compared with the corresponding groups.
When patients were categorized according to covariates, the aHRs were statistically lower in the SGLT2i group than in the control group, except in alcoholism patients, macular edema patients, without metformin, without sulphonylurea, and with GLP-1RA; the aHR were 0.72 (95% CI = 0.43–1.23), 0.78 (95% CI = 0.50–1.24), 0.71 (95% CI = 0.42–1.18), 0.82 (95% CI = 0.67–1.00), and 0.63 (95% CI = 0.40, 1.01), respectively (Table 3).
Discussions
The study investigates the use of SGLT2 inhibitors. SGLT2 inhibitors block the reabsorption of glucose by inhibiting SGLT2, promoting glucose renal excretion, lowering the elevated glucose levels of patients with diabetes, and producing an osmotic diuretic effect [18,19,20]. This study explored the association between SGLT2 inhibitors in patients with DM and the development of MD. The study used data from the Longitudinal Generation Tracking Database (LGTD), which was derived from a large database of a single-payer NHI program initiated in Taiwan since 1995, called the NHIRD. We aimed to explore the risk of MD in patients with diabetes treated with SGLT2 inhibitors. We found that the incidence of MD was lower in diabetic patients treated with SGLT2 inhibitors than in those treated without SGLT2 inhibitors. This may imply some positive correlation between SGLT2 inhibitors and the prevention of MD.
The mechanisms underlying the protective effect of SGLT2 inhibitors that reduce the risk of MD remain understudied. During the early stage of diabetic retinopathy, pericyte swelling and pericyte loss occur, which results in microaneurysm formation in the retina. The swollen pericytes lose their contractile ability and lead to retinal hyperperfusion [21, 22]. These processes result in a similar clinical observation as the early MD disease sign, edematous macula. The SGLT2 inhibitor has been proven to decrease inflammatory responses and oxidative processes, such as changing the phenotype of astrocytes and microglia into pro-inflammatory ones [22], which also plays a crucial role in MD disease. SGLT2 inhibitors elevate the ratios of adenosine diphosphate/adenosine triphosphate (ATP) and AMP/ATP, leading to a decrease in ATP production and oxidative phosphorylation. Consequently, cellular ATP levels are reduced, which triggers AMPK activation. AMPK activation hinders protein synthesis and cell proliferation. A previous study has shown that metformin exerts its anti-inflammatory and antioxidative effects primarily through the activation of AMP-activated protein kinase (AMPK). This activation leads to the inhibition of nuclear factor-kappa B, a reduction in reactive oxygen species, and the inhibition of the mammalian target of rapamycin. AMPK, a metabolic-sensing Ser/Thr kinase expressed in all cell types, plays a central role in maintaining energy homeostasis and regulating metabolic stress. It also contributes to the dysfunction of the metabolic ecosystem, potentially influencing the pathogenesis of age-related macular degeneration (AMD).
Metformin's protective effects against oxidative damage and mitochondrial dysfunction are considered additional mechanisms for its potential efficacy in AMD treatment [23]. These effects have been confirmed in retinal pigment epithelial (RPE) cells, where metformin stimulates autophagy through the activation of the AMPK pathway, effectively shielding RPE cells from oxidative damage. Furthermore, metformin safeguards photoreceptors and RPE cells from acute injury and delays inherited retinal degeneration by reducing oxidative stress and increasing mitochondrial energy production. Additionally, metformin demonstrates anti-inflammatory properties on the RPE by attenuating pro-inflammatory and adhesion molecule genes. This is particularly relevant in early AMD, characterized by drusen formation, as it results from an inflammatory reaction triggered by RPE damage. Thus, the anti-inflammatory and antioxidant effects of metformin help protect the RPE from early AMD lesions [13, 24]. Thus, in our study, SGLT2 inhibitors showed a similar effect to metformin and resulted in a decreased relative risk of MD in patients with DM.
Subretinal fibrosis and geographic atrophy are challenging clinical situations. Type IV collagen synthesis is increased under high-glucose conditions in bovine pericytes. SGLT2 inhibitors may inhibit mesangial expansion in the glomerulus and microvessel occlusion in the retina (22). Thus, the collagen synthesis modulation could be a positive impact on MD disease prevention.
The study has several strengths, such as the use of a large database, adjustment of potential confounders, and multivariate Cox proportional hazards models. However, the study has some limitations: It is a retrospective cohort study that could not determine the causal relationship between SGLT2 inhibitors and MD. Moreover, the study was conducted in Taiwan; therefore, the results may not be generalizable to other populations. Finally, the Image evaluation and results of hematology test are not available from NHIRD. However, all the patients who need anti-VEFG drugs to treat macular degeneration disease will turn in optical coherence tomography (OCT) image for audited. Similarly, all the patients who need anti-VEFG drugs to treating diabetic macular edema will turn in HbA1C data for audited. The data of HbA1C for first diagnosis should below 10%. Overall, the study suggests that SGLT2 inhibitors may have a protective effect on MD in patients with diabetes.
In conclusion, we found that SGLT2is has a stronger protective effect against MD in patients with diabetes than diuretics. SGLT2is may have benefits beyond glycemic control in patients with DR. Compared with other anti-diabetic drugs, SGLT2 inhibitors show strong ability of anti-inflammatory and antioxidant effects by regulating adenosine diphosphate/adenosine triphosphate (ATP) and AMP/ATP pathway. SGLT2 inhibitor may have a better chance to propone macular degeneration disease process and lead to the protecting effect. However, additional clinical and experimental studies are required.
Data availability
Information is accessible through the National Health Insurance Research Database (NHIRD) provided by the Taiwan National Health Insurance (NHI) Administration. However, due to legal constraints stipulated by the Taiwan government under the "Personal Information Protection Act," the data cannot be released to the public. If you wish to obtain the data, you may submit formal requests to the NHIRD via their website (https://dep.mohw.gov.tw/DOS/lp-2506-113.html).
References
Holden C, Foster B, Panasewicz S, Mehrotra L. US FDA approves INVOKANA™(Canagliflozin) for the treatment of adults with type 2 diabetes.
Patel RB (2023) Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in heart failure—does the story begin and end with the kidney? JAMA Cardiology.
Rizzo MR, Di Meo I, Polito R, Auriemma MC, Gambardella A, di Mauro G et al (2022) Cognitive impairment and type 2 diabetes mellitus: focus of SGLT2 inhibitors treatment. Pharmacol Res 176:106062
Idris I, Donnelly R (2009) Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 11:79–88
Yamashita K, Yoshiike S, Yamashita T, Mori JI, Aizawa T (2022) Reduction of severe hypoglycemic events among outpatients with type 2 diabetes following sodium-glucose cotransporter 2 inhibitor marketing in Japan. Horm Metab Res 54:747–753
Suzuki D, Yamada H, Yoshida M, Funazaki S, Amamoto M, Morimoto J et al (2020) Sodium-glucose cotransporter 2 inhibitors improved time-in-range without increasing hypoglycemia in Japanese patients with type 1 diabetes: a retrospective, single-center, pilot study. J Diabetes Investig 11:1230–1237
Farahani P (2018) Nonsevere hypoglycemia episode clinical and economic outcomes: a comparison between sulfonylurea and sodium-glucose cotransporter 2 inhibitor as add-on to metformin from a canadian perspective. Int J Endocrinol 2018:3718958
Verma S, McMurray JJV (2018) SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia 61:2108–2117
Vallon V, Verma S (2021) Effects of sglt2 inhibitors on kidney and cardiovascular function. Annu Rev Physiol 83:503–528
Waijer SW, Vart P, Cherney DZI, Chertow GM, Jongs N, Langkilde AM et al (2022) Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia 65:1085–1097
Jardine M, Zhou Z, Lambers Heerspink HJ, Hockham C, Li Q, Agarwal R et al (2021) Kidney, cardiovascular, and safety outcomes of canagliflozin according to baseline albuminuria: a CREDENCE secondary analysis. Clin J Am Soc Nephrol 16:384–395
Chen YY, Shen YC, Lai YJ, Wang CY, Lin KH, Feng SC et al (2019) Association between metformin and a lower risk of age-related macular degeneration in patients with type 2 diabetes. J Ophthalmol 2019:1649156
Jiang J, Chen Y, Zhang H, Yuan W, Zhao T, Wang N et al (2022) Association between metformin use and the risk of age-related macular degeneration in patients with type 2 diabetes: a retrospective study. BMJ Open 12:e054420
Tseng CH (2023) The risk of age-related macular degeneration is reduced in type 2 diabetes patients who use metformin. Pharm (Basel). 16:224.
Wang Y, Zhong Y, Zhang L, Wu Q, Tham Y, Rim TH et al (2022) Global incidence, progression, and risk factors of age-related macular degeneration and projection of disease statistics in 30 years: a modeling study. Gerontology 68:721–735
Lin KY, Hsih WH, Lin YB, Wen CY, Chang TJ (2021) Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy. J Diabetes Investig 12:1322–1325
Zhou B, Shi Y, Fu R, Ni H, Gu L, Si Y et al (2022) Relationship between SGLT-2i and ocular diseases in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne) 13:907340
Chao EC, Henry RR (2010) SGLT2 inhibition—a novel strategy for diabetes treatment. Nat Rev Drug Discovery 9:551–559
Dardi I, Kouvatsos T, Jabbour S (2016) SGLT2 inhibitors. Biochem Pharmacol 101:27–39
Masuda T, Muto S, Fukuda K, Watanabe M, Ohara K, Koepsell H et al (2020) Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume. Physiol Rep 8:e14360
Wakisaka M, Nagao T (2017) Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy. Glycobiology 27:691–695
Pawlos A, Broncel M, Woźniak E, Gorzelak-Pabiś P (2021) Neuroprotective effect of SGLT2 inhibitors. Molecules 26:7213
Brown EE, Ball JD, Chen Z, Khurshid GS, Prosperi M, Ash JD (2019) The common antidiabetic drug metformin reduces odds of developing age-related macular degeneration. Invest Ophthalmol Vis Sci 60:1470–1477
Blitzer AL, Ham SA, Colby KA, Skondra D (2021) Association of metformin use with age-related macular degeneration: a case-control study. JAMA Ophthalmol 139:302–309
Acknowledgements
We express our gratitude to the Health Data Science Center at China Medical University Hospital for their generous provision of administrative, technical, and financial assistance.
Funding
This study is supported in part by Tungs’ Taichung Metro Harbor Hospital research grant (TTMHH-R1130010; TTMHH-R1130011), the Ministry of Science and Technology (MOHW112-TDU-B-212–144004), China Medical University Hospital (DMR-111–105; DMR-112–087; DMR-113–009). The funders had no role in the study design, data collection and analysis, the decision to publish, or the preparation of the manuscript. No additional external funding was received for this study.
Author information
Authors and Affiliations
Contributions
Conceptualization, K.-H.C., K.-S. L. and M.-Y. H.; methodology, K.-H.C. and T.-S. Y.; software, K.-H.C. and T.-S. Y.; validation, K.-H.C. and M.-Y. H.; formal analysis, K.-H.C. H.-J. L. and T.-S. Y.; investigation, all authors; resources, F.-J. T., and K.-H.C.; data curation, K.-H.C., H.-J. L. and T.-S. Y.; writing—original draft preparation, M.-Y. H., K.-S. L., and K.-H.C.; writing—review and editing, K.-H.C.,C.-C.C.,K.-S. L. and M.-Y. H.; visualization, all authors; supervision, K.-H.C.; project administration, F.-J. T., and K.-H.C; funding acquisition, F.-J. T., and K.-H.C.. All authors have read and agreed to the published version of the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Ethical approval
The NHIRD secures patient personal data by employing encryption to safeguard privacy. It also provides researchers with anonymous identification numbers that are associated with relevant claims data, including details such as gender, date of birth, medical services, and prescriptions. As a result, patient consent is not required to access the NHIRD for this research project. This research project received approval for exemption from the Institutional Review Board (IRB) at China Medical University (Approval Number CMUH109-REC2-031 (CR2)), and the IRB explicitly waived the requirement for informed consent. All the procedures were followed by the relevant guidelines and regulations.
Consent to participate
This research project obtained an exemption approval from the Institutional Review Board (IRB) at China Medical University (Approval Number CMUH109-REC2-031 (CR2)), and the IRB explicitly waived the need for consent.
Consent for publication
Not applicable.
Additional information
Managed By Massimo Federici.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Hsu, MY., Luo, KS., Chou, CC. et al. Association between sodium–glucose cotransporter-2 (SGLT2) inhibitors and macular degeneration in patients with diabetes: a nationwide population-based study in Taiwan. Acta Diabetol 61, 1161–1168 (2024). https://doi.org/10.1007/s00592-024-02303-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-024-02303-3